Navigation Links
XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
Date:5/7/2008

ing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This annual report was filed with the SEC on March 17, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurre
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces First Quarter 2008 Financial Results
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets has announced the ... Strategic Business Report" report to their offering. ... Hormone Drugs in US$ Million by the following Brands: Humatrope, ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , and Rest of ...
(Date:8/19/2014)... -- Avizia, Inc., a leading provider of cutting-edge telemedicine ... financing round led by NextGen Angels along with Blu ... be used to continue to fuel the rapidly growing ... Edward Kennedy , CEO and president of Tollgrade Communications, ... Kurtzman , CFO of newBrandAnalytics, who joined the board ...
(Date:8/19/2014)... 19, 2014  SCILEX Pharmaceuticals, Inc., a company engaged ... for the treatment of pain, announced that it had formed ... Jeff Gudin , Dr. Charles Argoff , ... Vought . SCILEX Chief Executive Officer ... board would greatly assist in the development and commercialization ...
Breaking Medicine Technology:Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Avizia Closes Funding Round 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4
(Date:8/20/2014)... In a recent article published by the ... (UCL) study showed that dental experts from around the ... was the most effective. Analysis of 66 different advice ... frequently recommended, but none were favored by a majority. ... experienced cosmetic dentist Dr. Patrick J. Broome, DMD, ...
(Date:8/20/2014)... 20, 2014 Biosimilars, which are ... approved through an abbreviated process, could reap billions ... Atlantic Information Services, Inc.’s (AIS) Specialty Pharmacy News ... including the Food and Drug Administration’s (FDA) recent ... towards approval. , Drugmaker Sandoz said July 24 ...
(Date:8/20/2014)... August 20, 2014 “Have you recently been ... accident and personal injury lawyer serving the greater Seattle area. ... If so, then keep reading . , In a ... injured in an auto accident can use to see if ... that a personal injury insurance claim will allow an individual ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 First ... freestanding emergency rooms in the United States, named Richard ... – FM 685 facility. , “We are pleased ... medical director of our second facility in Pflugerville,” said ... Choice Emergency Room. , Dr. Daniels received his ...
Breaking Medicine News(10 mins):Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2
... , , MIAMI, ... toys manufactured in China sent parents searching frantically for gifts ... refunds suggested that even so-called educational toys are suspect. Renowned ... are actually harmful to developing brains, retarding language development and ...
... , LONDON, Dec. 7 The National Health ... people in the UK, understands the value of an engaged ... initiative to improve the value of care, many NHS hospitals ... Tanner Company, to train hospital leaders. , "Staff engagement is ...
... , , BOCA RATON, ... the market leader in all-natural herbal and homeopathic remedies for ... as their PR firm of record. The company,s two brands, ... provide complete lines of safe, scientifically-tested, guaranteed products that promote ...
... ... has begun his work as the new worldwide executive director of the Drug Information ... ... MBA, CAE, officially has begun his work as the new worldwide executive director of ...
... , PARSIPPANY, N.J., Dec. 7 Today the Centers for ... Vaccination Week. While the week was designed to highlight the importance ... taking additional steps to keep you and your family healthy during ... , "It,s easy to get overwhelmed by all the information circulating ...
... may be able to reverse some of the damage to ... their cigarettes, according to research out of the University of ... in the December 15 issue of the American Thoracic Society,s ... "We found that exposure to cigarette smoke appears to ...
Cached Medicine News:Health News:Top 10 Toys That Will Scar Your Child for Life 2Health News:The NHS to Improve Patient Care by Better Engaging Staff 2Health News:Native Remedies and PetAlive.com Hires TransMedia Group to Herald Herbal for People and Pets 2Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 2Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 3Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Quitting smoking can reverse asthma-inducing changes in lungs 2
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum....
For the quantitative colorimetric determination of AST (SGOT) in serum....
Medicine Products: